Autifony to present preclinical data supporting the efficacy of its novel clinical-stage Kv3 modulators

Autifony to present preclinical data supporting the efficacy of its novel clinical-stage Kv3 modulators to address cellular dysfunction, ataxia, and seizure susceptibility in PME (Progressive Myoclonic Epilepsy, EPM7) at the American Epilepsy Society (AES) Annual Meeting, taking place 2-6 December 2022 in Nashville, Tennessee.